DnB Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

DnB Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Hold	1,107	–	–	﹤0.01%	953
2026 Q1	$221K	Buy	+1,107	New	+$219K	﹤0.01%	1118

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DnB Asset Management's LGND Position: Q2 2026 in Review

DnB Asset Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 1,107 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

DnB Asset Management first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

DnB Asset Management held 1,107 shares of Ligand Pharmaceuticals worth $350K as of Q2 2026.
DnB Asset Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #953 holding.
DnB Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.